Insider transactions

EDGAR

TRANSCODE THERAPEUTICS, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-19.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–5 of 5

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-09-09 Filed 2026-09-11Fitzgerald Thomas A Director · Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (185,000) — exercise price 1.78
Acquired (A)185,0000.00
0

Derived: shares × price per share. Exact value 0.00.

185,000Direct (D) No
F1
  • F1 The shares underlying this option shall vest and become exercisable in twelve (12) equal monthly installments following the grant date.
Open filing 0001104659-26-107120 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-05DEFJ, LLC 10% ownerCK Life Sciences Intl (Holdings) Inc 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)11,813,859——12,113,899Direct (D) No
F1, F2, F3
  • F1 Each of the Issuer's (i) Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (Series A Non-Voting Convertible Preferred Stock) and (ii) Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (Series B Non-Voting Convertible Preferred Stock), are convertible at any time into shares of Common Stock, par value $0.0001 per share (Common Stock), with each share of Series A Non-Voting Convertible Preferred Stock or Series B Non-Voting Convertible Preferred Stock, as applicable, convertible into 10,000 shares of Common Stock. Neither the shares of Series A Non-Voting Convertible Preferred Stock nor the shares of Series B Non-Voting Convertible Preferred Stock have an expiration date.
  • F2 On August 3, 2026, DEFJ, LLC (DEFJ) (i) submitted a notice to the Issuer providing that it waived the Beneficial Ownership Limitation (as defined in the Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock (Certificate of Designation)) set forth in Section 6.3.3 of the Certificate of Designation, effective as of August 3, 2026, and (ii) submitted an irrevocable conversion notice to the Issuer providing that DEFJ converts 1,181.3859 shares of Series A Non-Voting Convertible Preferred Stock into 11,813,859 shares of Common Stock and 202.0582 shares of Series B Non-Voting Convertible Preferred Stock into 2,020,582 shares of Common Stock.
  • F3 DEFJ, a Delaware limited liability company, is a direct, wholly owned subsidiary of Conjoint Inc., a Delaware corporation, which is a direct, wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company, which is a direct, wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company, which is a direct, wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc. (CKLS). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an admission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.
Open filing 0001104659-26-091078 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-05DEFJ, LLC 10% ownerCK Life Sciences Intl (Holdings) Inc 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)2,020,582——14,134,481Direct (D) No
F1, F2, F3
  • F1 Each of the Issuer's (i) Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (Series A Non-Voting Convertible Preferred Stock) and (ii) Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (Series B Non-Voting Convertible Preferred Stock), are convertible at any time into shares of Common Stock, par value $0.0001 per share (Common Stock), with each share of Series A Non-Voting Convertible Preferred Stock or Series B Non-Voting Convertible Preferred Stock, as applicable, convertible into 10,000 shares of Common Stock. Neither the shares of Series A Non-Voting Convertible Preferred Stock nor the shares of Series B Non-Voting Convertible Preferred Stock have an expiration date.
  • F2 On August 3, 2026, DEFJ, LLC (DEFJ) (i) submitted a notice to the Issuer providing that it waived the Beneficial Ownership Limitation (as defined in the Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock (Certificate of Designation)) set forth in Section 6.3.3 of the Certificate of Designation, effective as of August 3, 2026, and (ii) submitted an irrevocable conversion notice to the Issuer providing that DEFJ converts 1,181.3859 shares of Series A Non-Voting Convertible Preferred Stock into 11,813,859 shares of Common Stock and 202.0582 shares of Series B Non-Voting Convertible Preferred Stock into 2,020,582 shares of Common Stock.
  • F3 DEFJ, a Delaware limited liability company, is a direct, wholly owned subsidiary of Conjoint Inc., a Delaware corporation, which is a direct, wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company, which is a direct, wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company, which is a direct, wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc. (CKLS). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an admission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.
Open filing 0001104659-26-091078 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-05DEFJ, LLC 10% ownerCK Life Sciences Intl (Holdings) Inc 10% owner
C

Conversion of derivative security

Derivative security: Series A Non-Voting Convertible Preferred Stock — underlying Common Stock (11,813,859)
Disposed (D)1,181.38590—0Direct (D) No
F1, F2, F4, F3
  • F1 Each of the Issuer's (i) Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (Series A Non-Voting Convertible Preferred Stock) and (ii) Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (Series B Non-Voting Convertible Preferred Stock), are convertible at any time into shares of Common Stock, par value $0.0001 per share (Common Stock), with each share of Series A Non-Voting Convertible Preferred Stock or Series B Non-Voting Convertible Preferred Stock, as applicable, convertible into 10,000 shares of Common Stock. Neither the shares of Series A Non-Voting Convertible Preferred Stock nor the shares of Series B Non-Voting Convertible Preferred Stock have an expiration date.
  • F2 On August 3, 2026, DEFJ, LLC (DEFJ) (i) submitted a notice to the Issuer providing that it waived the Beneficial Ownership Limitation (as defined in the Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock (Certificate of Designation)) set forth in Section 6.3.3 of the Certificate of Designation, effective as of August 3, 2026, and (ii) submitted an irrevocable conversion notice to the Issuer providing that DEFJ converts 1,181.3859 shares of Series A Non-Voting Convertible Preferred Stock into 11,813,859 shares of Common Stock and 202.0582 shares of Series B Non-Voting Convertible Preferred Stock into 2,020,582 shares of Common Stock.
  • F4 Includes 28.4291 shares of Series A Non-Voting Convertible Preferred Stock previously issued to DEFJ as a payment-in-kind dividend that was exempt from Section 16 pursuant to Rule 16a-9 under the Securities Exchange Act of 1934, as amended.
  • F3 DEFJ, a Delaware limited liability company, is a direct, wholly owned subsidiary of Conjoint Inc., a Delaware corporation, which is a direct, wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company, which is a direct, wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company, which is a direct, wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc. (CKLS). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an admission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.
Open filing 0001104659-26-091078 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-05DEFJ, LLC 10% ownerCK Life Sciences Intl (Holdings) Inc 10% owner
C

Conversion of derivative security

Derivative security: Series B Non-Voting Convertible Preferred Stock — underlying Common Stock (2,020,582)
Disposed (D)202.05820—0Direct (D) No
F1, F2, F3
  • F1 Each of the Issuer's (i) Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (Series A Non-Voting Convertible Preferred Stock) and (ii) Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (Series B Non-Voting Convertible Preferred Stock), are convertible at any time into shares of Common Stock, par value $0.0001 per share (Common Stock), with each share of Series A Non-Voting Convertible Preferred Stock or Series B Non-Voting Convertible Preferred Stock, as applicable, convertible into 10,000 shares of Common Stock. Neither the shares of Series A Non-Voting Convertible Preferred Stock nor the shares of Series B Non-Voting Convertible Preferred Stock have an expiration date.
  • F2 On August 3, 2026, DEFJ, LLC (DEFJ) (i) submitted a notice to the Issuer providing that it waived the Beneficial Ownership Limitation (as defined in the Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock (Certificate of Designation)) set forth in Section 6.3.3 of the Certificate of Designation, effective as of August 3, 2026, and (ii) submitted an irrevocable conversion notice to the Issuer providing that DEFJ converts 1,181.3859 shares of Series A Non-Voting Convertible Preferred Stock into 11,813,859 shares of Common Stock and 202.0582 shares of Series B Non-Voting Convertible Preferred Stock into 2,020,582 shares of Common Stock.
  • F3 DEFJ, a Delaware limited liability company, is a direct, wholly owned subsidiary of Conjoint Inc., a Delaware corporation, which is a direct, wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company, which is a direct, wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company, which is a direct, wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc. (CKLS). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an admission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.
Open filing 0001104659-26-091078 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,905 filings read, the latest filed 2026-11-18. Prior quarter ending 2026-06-30: 9,170 filings read.

Showing 1–13 of 13

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Yorkville Advisors Global, LP 75,786 SH127,320 dollarsHigher by 56,147 Prior quarter: 19,639Open filing 0001104659-26-126193 Filed 2026-11-12 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager10,207 SH17,148 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 6,545 SH10,996 dollarsUnchanged Prior quarter: 6,545Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
VANGUARD FIDUCIARY TRUST CO 2,982 SH5,010 dollarsUnchanged Prior quarter: 2,982Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
UBS Group AG Partly reported under another manager2,650 SH4,452 dollarsLower by 238 Prior quarter: 2,888Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Tower Research Capital LLC (TRC) Partly reported under another manager1,746 SH2,934 dollarsHigher by 1,069 Prior quarter: 677Open filing 0001533421-26-000010 Filed 2026-11-16 Dispute this row
OSAIC HOLDINGS, INC. Partly reported under another manager270 SH453 dollarsNot in the prior quarter’s filings read Open filing 0001677044-26-000011 Filed 2026-11-12 Dispute this row
Robinhood Markets, Inc. 102 SH168 dollarsNot in the prior quarter’s filings read Open filing 0000950157-26-001278 Filed 2026-11-18 Dispute this row
WELLS FARGO COMPANY/MN Partly reported under another manager55 SH92 dollarsUnchanged Prior quarter: 55Open filing 0000072971-26-000342 Filed 2026-11-16 Dispute this row
SBI Securities Co., Ltd. 12 SH20 dollarsUnchanged Prior quarter: 12Open filing 0001851815-26-000004 Filed 2026-10-22 Dispute this row
FMR LLC Partly reported under another manager11 SH18 dollarsLower by 695 Prior quarter: 706Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
IFP Advisors, Inc Partly reported under another manager8 SH13 dollarsNot in the prior quarter’s filings read Open filing 0001641866-26-000005 Filed 2026-10-16 Dispute this row
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 1 SH2 dollarsNot in the prior quarter’s filings read Open filing 0001085146-26-000940 Filed 2026-11-13 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • MERCER GLOBAL ADVISORS INC /ADV 1,535 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
DEFJ, LLC Common Stock83.914,134,481.0008/03/2026 Filed 2026-08-03SCHEDULE 13D/AAmendment 5Open filing 0001104659-26-089819 Dispute this row
CK Life Sciences Int'l., (Holdings) Inc. Common Stock83.914,134,481.0008/03/2026 Filed 2026-08-03SCHEDULE 13D/AAmendment 5Open filing 0001104659-26-089819 Dispute this row
DEFJ, LLC Common Stock83.914,134,481.0007/27/2026 Filed 2026-07-27SCHEDULE 13D/AAmendment 4Open filing 0001104659-26-087098 Dispute this row
CK Life Sciences Int'l., (Holdings) Inc. Common Stock83.914,134,481.0007/27/2026 Filed 2026-07-27SCHEDULE 13D/AAmendment 4Open filing 0001104659-26-087098 Dispute this row
Elena Rosa Braci Common Stock, par value $0.0001 per share6.17186,236.0007/23/2026 Filed 2026-07-28SCHEDULE 13GOpen filing 0001493152-26-035075 Dispute this row
Daniel Eduardo Katzman Common Stock, par value $0.0001 per share5.16155,611.0007/23/2026 Filed 2026-07-28SCHEDULE 13GOpen filing 0001493152-26-035074 Dispute this row
Unleash Immuno Oncolytics, Inc. Common Stock, par value $0.0001 per share9.94300,000.0007/23/2026 Filed 2026-07-28SCHEDULE 13GOpen filing 0001493152-26-035076 Dispute this row
DEFJ, LLC Common Stock9.9300,040.0007/23/2026 Filed 2026-07-23SCHEDULE 13D/AAmendment 3Open filing 0001104659-26-086266 Dispute this row
CK Life Sciences Int'l., (Holdings) Inc. Common Stock9.9300,040.0007/23/2026 Filed 2026-07-23SCHEDULE 13D/AAmendment 3Open filing 0001104659-26-086266 Dispute this row
DEFJ, LLC Common Stock8.883,285.0007/17/2026 Filed 2026-07-17SCHEDULE 13D/AAmendment 2Open filing 0001104659-26-084636 Dispute this row
CK Life Sciences Int'l., (Holdings) Inc. Common Stock8.883,285.0007/17/2026 Filed 2026-07-17SCHEDULE 13D/AAmendment 2Open filing 0001104659-26-084636 Dispute this row
YA II PN, Ltd. Common Stock, $0.0001 par value per share9.9101,772.0004/15/2026 Filed 2026-04-20SCHEDULE 13GOpen filing 0001104659-26-045551 Dispute this row
YA Global Investments II (U.S.), LP Common Stock, $0.0001 par value per share9.9101,772.0004/15/2026 Filed 2026-04-20SCHEDULE 13GOpen filing 0001104659-26-045551 Dispute this row
Yorkville Advisors Global, LP Common Stock, $0.0001 par value per share9.9101,772.0004/15/2026 Filed 2026-04-20SCHEDULE 13GOpen filing 0001104659-26-045551 Dispute this row
Yorkville Advisors Global II, LLC Common Stock, $0.0001 par value per share9.9101,772.0004/15/2026 Filed 2026-04-20SCHEDULE 13GOpen filing 0001104659-26-045551 Dispute this row
YAII GP, LP Common Stock, $0.0001 par value per share9.9101,772.0004/15/2026 Filed 2026-04-20SCHEDULE 13GOpen filing 0001104659-26-045551 Dispute this row
YAII GP II, LLC Common Stock, $0.0001 par value per share9.9101,772.0004/15/2026 Filed 2026-04-20SCHEDULE 13GOpen filing 0001104659-26-045551 Dispute this row
Mark Angelo Common Stock, $0.0001 par value per share9.9101,772.0004/15/2026 Filed 2026-04-20SCHEDULE 13GOpen filing 0001104659-26-045551 Dispute this row
SC-Sigma Global Partners, LP Common Stock, $0.0001 par value per share9.9101,772.0004/15/2026 Filed 2026-04-20SCHEDULE 13GOpen filing 0001104659-26-045551 Dispute this row
SABBY MANAGEMENT, LLC Common Stock4.941,601.0012/31/2025 Filed 2026-01-07SCHEDULE 13G/AAmendment 1Open filing 0001535610-26-000003 Dispute this row
SABBY VOLATILITY WARRANT MASTER FUND LTD Common Stock4.941,601.0012/31/2025 Filed 2026-01-07SCHEDULE 13G/AAmendment 1Open filing 0001535610-26-000003 Dispute this row
HAL MINTZ Common Stock4.941,601.0012/31/2025 Filed 2026-01-07SCHEDULE 13G/AAmendment 1Open filing 0001535610-26-000003 Dispute this row
CK Life Sciences Int'l., (Holdings) Inc. Common Stock9.183,285.0010/27/2025 Filed 2025-10-28SCHEDULE 13D/AAmendment 1Open filing 0001104659-25-103292 Dispute this row
DEFJ, LLC Common Stock9.183,285.0010/27/2025 Filed 2025-10-28SCHEDULE 13D/AAmendment 1Open filing 0001104659-25-103292 Dispute this row
CK Life Sciences Int'l., (Holdings) Inc. Common Stock9.183,285.0010/08/2025 Filed 2025-10-16SCHEDULE 13DOpen filing 0001104659-25-100081 Dispute this row
DEFJ, LLC Common Stock9.183,285.0010/08/2025 Filed 2025-10-16SCHEDULE 13DOpen filing 0001104659-25-100081 Dispute this row
THE GOLDMAN SACHS GROUP, INC. Common Stock, par value $0.0001 per share0.082.0009/30/2025 Filed 2025-11-10SCHEDULE 13G/AAmendment 1Open filing 0000886982-25-001440 Dispute this row
GOLDMAN SACHS CO. LLC Common Stock, par value $0.0001 per share0.082.0009/30/2025 Filed 2025-11-10SCHEDULE 13G/AAmendment 1Open filing 0000886982-25-001440 Dispute this row
Anson Funds Management LP Common Stock, $0.0001 par value0.127,12506/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 1Open filing 0000950170-25-109220 Dispute this row
Anson Management GP LLC Common Stock, $0.0001 par value0.127,12506/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 1Open filing 0000950170-25-109220 Dispute this row
Tony Moore Common Stock, $0.0001 par value0.127,12506/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 1Open filing 0000950170-25-109220 Dispute this row
Anson Advisors Inc. Common Stock, $0.0001 par value0.127,12506/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 1Open filing 0000950170-25-109220 Dispute this row
Amin Nathoo Common Stock, $0.0001 par value0.127,12506/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 1Open filing 0000950170-25-109220 Dispute this row
Moez Kassam Common Stock, $0.0001 par value0.127,12506/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 1Open filing 0000950170-25-109220 Dispute this row
THE GOLDMAN SACHS GROUP, INC. Common Stock, par value $0.0001 per share5.949,018.0006/30/2025 Filed 2025-08-14SCHEDULE 13GOpen filing 0000769993-25-000533 Dispute this row
GOLDMAN SACHS CO. LLC Common Stock, par value $0.0001 per share5.949,018.0006/30/2025 Filed 2025-08-14SCHEDULE 13GOpen filing 0000769993-25-000533 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,540,664 filings read, dated 2004-06-14 to 2026-11-18: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201517,857
2016222,642
2017222,009
2018223,345
2019216,482
2020166,957
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026262,403

Filings made before the SEC required XML are listed, not extracted.

Back to TRANSCODE THERAPEUTICS, INC.